DTI-MHAPR: optimized drug-target interaction prediction via PCA-enhanced features and heterogeneous graph attention networks
שמור ב:
| הוצא לאור ב: | BMC Bioinformatics vol. 26 (2025), p. 1 |
|---|---|
| מחבר ראשי: | |
| מחברים אחרים: | , , , , |
| יצא לאור: |
Springer Nature B.V.
|
| נושאים: | |
| גישה מקוונת: | Citation/Abstract Full Text Full Text - PDF |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3165418153 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1471-2105 | ||
| 024 | 7 | |a 10.1186/s12859-024-06021-z |2 doi | |
| 035 | |a 3165418153 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 58459 |2 nlm | ||
| 100 | 1 | |a Yang, Guang | |
| 245 | 1 | |a DTI-MHAPR: optimized drug-target interaction prediction via PCA-enhanced features and heterogeneous graph attention networks | |
| 260 | |b Springer Nature B.V. |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Drug-target interactions (DTIs) are pivotal in drug discovery and development, and their accurate identification can significantly expedite the process. Numerous DTI prediction methods have emerged, yet many fail to fully harness the feature information of drugs and targets or address the issue of feature redundancy. We aim to refine DTI prediction accuracy by eliminating redundant features and capitalizing on the node topological structure to enhance feature extraction. To achieve this, we introduce a PCA-augmented multi-layer heterogeneous graph-based network that concentrates on key features throughout the encoding-decoding phase. Our approach initiates with the construction of a heterogeneous graph from various similarity metrics, which is then encoded via a graph neural network. We concatenate and integrate the resultant representation vectors to merge multi-level information. Subsequently, principal component analysis is applied to distill the most informative features, with the random forest algorithm employed for the final decoding of the integrated data. Our method outperforms six baseline models in terms of accuracy, as demonstrated by extensive experimentation. Comprehensive ablation studies, visualization of results, and in-depth case analyses further validate our framework’s efficacy and interpretability, providing a novel tool for drug discovery that integrates multimodal features. | |
| 653 | |a Feature extraction | ||
| 653 | |a Deep learning | ||
| 653 | |a Datasets | ||
| 653 | |a Network topologies | ||
| 653 | |a Drug interactions | ||
| 653 | |a Bioinformatics | ||
| 653 | |a Multilayers | ||
| 653 | |a Data mining | ||
| 653 | |a Principal components analysis | ||
| 653 | |a Optimization | ||
| 653 | |a Ablation | ||
| 653 | |a Feature selection | ||
| 653 | |a Drug development | ||
| 653 | |a Redundancy | ||
| 653 | |a Proteins | ||
| 653 | |a Predictions | ||
| 653 | |a Graph neural networks | ||
| 653 | |a Drug discovery | ||
| 653 | |a Neural networks | ||
| 653 | |a Algorithms | ||
| 653 | |a Ligands | ||
| 653 | |a Resultants | ||
| 653 | |a Encoding-Decoding | ||
| 653 | |a Methods | ||
| 653 | |a Information processing | ||
| 653 | |a Graphical representations | ||
| 653 | |a Semantics | ||
| 653 | |a Environmental | ||
| 700 | 1 | |a Liu, Yinbo | |
| 700 | 1 | |a Wen, Sijian | |
| 700 | 1 | |a Chen, Wenxi | |
| 700 | 1 | |a Zhu, Xiaolei | |
| 700 | 1 | |a Wang, Yongmei | |
| 773 | 0 | |t BMC Bioinformatics |g vol. 26 (2025), p. 1 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3165418153/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3165418153/fulltext/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3165418153/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch |